Sustainability Home  > Company Profile

Company Profile

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhance human life. Bristol-Myers Squibb's 41,000 employees are dedicated to discovering, developing and providing innovative medicines that address significant unmet medical needs of patients worldwide. By living our mission and building our company for well over a century, we are also making a difference in the lives of our shareholders, employees and neighbors.

Major Products

Bristol-Myers Squibb manufactures hundreds of different products and is a leader in the discovery and manufacture of innovative therapies for cardiovascular disease, central nervous system disorders, oncology, virology, metabolics, and immunology. The Company also manufactures and markets ostomy care, advanced wound care, nutritional supplements, and infant formulas.

Bristol-Myers Squibb has two segments – Pharmaceuticals and Mead Johnson Nutritionals. Mead Johnson continues to be the leader in the U.S. infant formula market.

back to topPharmaceuticals

The Company is implementing a new strategy to discover and develop innovative medicines that address areas of significant unmet medical need. These areas include: affective (psychiatric) disorders, Alzheimer’s/dementia, atherosclerosis/thrombosis, diabetes, hepatitis, HIV/AIDS, obesity, oncology, rheumatoid arthritis and related diseases, and solid organ transplant. The Company continuously strives to create better treatments for patients by building a high quality drug discovery and development pipeline.

"We’re executing our company strategy by focusing R&D in areas of significant unmet medical need. Since 2002, we have launched eight new pharmaceutical products, including four since the beginning of 2006. Our R&D organization continues to be productive, thanks to the talent, dedication and commitment of thousands of scientists and other research staff. This productivity is also tied to our increased investments in R&D in recent years. Over the past three years, we have boosted companywide R&D expenditures 11 percent per year on a compounded annual growth rate basis. This commitment of people and resources drives our R&D efforts to develop the innovative medicines and health care products that patients need."

Elliott Sigal
Chief Scientific Officer and President, Pharmaceutical Research Institute

Our manufacturing facilities around the world are focused on quality and efficiency in delivering on the Company's mission.

"At Technical Operations, sustainability is an integral part of our global manufacturing strategy that drives our vision to become the highest quality, most reliable and admired supply organization in the pharmaceutical industry. Our employees are committed to our mission of extending and enhancing human life by supplying the company's innovative medicines to patients with serious diseases while upholding the highest levels of safety, quality, and compliance with worldwide regulations.  We are building new facilities and enhancing our existing facilities using the latest thinking and technologies that incorporate environmental, safety and energy efficiencies. Through our Sustainability 2010 Goals, we have been successful in reducing our energy and water consumption, and we continue to enhance our manufacturing processes to the benefit of the environment, our operational efficiency and the communities in which we operate."

Carlo de Notaristefani
President, Technical Operations, Bristol-Myers Squibb

 

back to topMead Johnson Nutritionals

Mead Johnson Nutritionals manufactures and markets infant formulas globally. In addition to our routine infant formulas, Mead Johnson also has a broad range of specialty formulas for infants and children with inborn errors of metabolism. Outside the United States, Mead Johnson has a full line of infant formulas as well as several nutritional products for toddlers, children and adults.

"Mead Johnson Nutritionals is a world leader in nutrition, dedicated to helping provide infants and children around the world with the best start in life. Health care providers and mothers know us for our Enfamil/Enfalac infant and toddler formulas, which comprise Bristol-Myers Squibb’s third-largest brand. For more than 100 years, we have been innovators in the development of routine and tolerance infant formulas, toddler beverages, vitamins and special metabolic products. As part of Bristol-Myers Squibb’s mission to extend and enhance human life, we’re committed to continuing to improve these products with the latest advances in science-based nutrition."

Steve Golsby
President, Mead Johnson Nutritionals

 

back to topLocation of Operations

Bristol-Myers Squibb operates approximately 60 research and development, manufacturing, and distribution facilities in more than 20 countries on six continents. We have people working in nearly 200 countries around the globe. Detailed information about our operating facilities can be found in the Facility Information section.

"Bristol-Myers Squibb is a company of great people who take pride in making a difference in the lives of people around the world. Our employees understand the struggles people sometimes face, trying to get the medicines they need to fight serious diseases. That’s why we work with doctors and others to improve access to medicines for those who are underserved. It’s part of the focus we put on partnering with doctors and patients, so we understand their concerns, their struggles, and their ideas for improving health care. After all, we are working together for the same goal: to help enhance and extend human life."

Tony Hooper
President, U.S. Pharmaceuticals

We have a major presence in the United States, Europe, Latin America, Asia, and other markets. We are a leader in emerging markets such as Brazil, Mexico, and China.

back to topOwnership and Markets Served

Bristol-Myers Squibb is a publicly traded pharmaceutical company with related health care businesses, listed on the New York Stock Exchange (NYSE: BMY). Our products are sold principally to wholesalers and retailers. Certain products are also sold to other drug manufacturers, hospitals, and the medical profession.

back to topScale of Activity

2007 Sales
(percentage of $19.3 billion US dollars)

By Region

United States
56%
Europe, Mid-East, Africa
24%
Other Western Hemisphere
9%
Pacific
11%

By Business Segment

Pharmaceuticals
81%
Nutritionals
13%
ConvaTec*
6%

*ConvaTec was divested as of August 1, 2008.

Bristol-Myers Squibb's worldwide sales are shown in the following table:

 
Worldwide Sales
2005
$19,207 million
2006
$17,914 million
2007*
$19,348 million
2006-2007 change
8%

*2007, restated to exclude the results related to the Medical Imaging business

In 2007, we invested $3.3 billion on pharmaceutical R&D, an amount that represents 20 percent of our pharmaceutical sales.

Stakeholders

Our stakeholders are similar to those of other major corporations. They encompass interested parties, both internal and external to the company and include:

  • Customers and consumers
  • Employees and their families
  • Retirees
  • Shareholders and investor groups
  • Suppliers and contractors
  • Neighbors and community groups
  • Regulators, legislators, and political leaders
  • Non-governmental organizations (NGOs)
  • Academia

To help make this website more useful to our readers, we used a process for engaging stakeholder input, which is described in the section on stakeholder relationships.

back to top


Last updated August 3, 2008 . Italicized product names are registered trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Copyright © 1998-2006 Bristol-Myers Squibb Company. Your use of the information on this site is subject to the terms of our Legal Notices.

 

On this page:

Major Products

Pharmaceuticals

Mead Johnson Nutritionals

Other Health Care Businesses

Location of Operations

Ownership & Markets Served

Scale of Activity

Stakeholders

Access to Information

The economic components of our sustainable development activities are covered in our company's Annual Report, while our EHS activities are summarized in this website. Our social activities are discussed in both of these documents, as well as in our corporate social responsibility report. To get a more complete picture of our performance, this website and both reports should be taken together as a comprehensive overview of our progress toward sustainable development.

Copies of reports can be requested from this website.

For more information, contact us.

About this Report

Company profile

Pledge

Customer Information

Supplier Information

Contractor Information

Student Information

Members of the Community

Benchmarking

Awards

Glossary

Links